These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 12154277)

  • 21. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    Wang Y; Wang Y; Zhao X; Liu L; Wang D; Wang C; Wang C; Li H; Meng X; Cui L; Jia J; Dong Q; Xu A; Zeng J; Li Y; Wang Z; Xia H; Johnston SC;
    N Engl J Med; 2013 Jul; 369(1):11-9. PubMed ID: 23803136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antithrombotic therapy in ischemic stroke and transient ischemic attack].
    Overgaard K; Poulsen TS; Husted SE
    Ugeskr Laeger; 2007 Oct; 169(40):3379-82. PubMed ID: 17953858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clopidogrel plus aspirin for stroke prevention.
    Alberts MJ; Easton JD
    Stroke; 2002 Nov; 33(11):2546-7; author reply 2546-7. PubMed ID: 12411639
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
    Aw D; Sharma JC
    Postgrad Med J; 2012 Jan; 88(1035):34-7. PubMed ID: 22121248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Secondary prevention with clopidogrel after TIA or stroke].
    Zuurbier SM; Vermeer SE; Hilkens PH; Algra A; Roos YB
    Ned Tijdschr Geneeskd; 2013; 157(25):A5836. PubMed ID: 23777963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin therapy should be first line: probably, but watch this space.
    Donnan GA; Davis SM
    Stroke; 2002 Aug; 33(8):2139-40. PubMed ID: 12154278
    [No Abstract]   [Full Text] [Related]  

  • 27. [Secondary prevention of stroke with antiplatelet drugs].
    Diener HC
    Med Klin (Munich); 2004 Aug; 99 Suppl 1():21-5. PubMed ID: 15487854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
    Hankey GJ; Eikelboom JW
    Neurology; 2005 Apr; 64(7):1117-21. PubMed ID: 15824331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
    Sprigg N; Gray LJ; England T; Willmot MR; Zhao L; Sare GM; Bath PM
    PLoS One; 2008 Aug; 3(8):e2852. PubMed ID: 18682741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
    Malloy RJ; Kanaan AO; Silva MA; Donovan JL
    Clin Ther; 2013 Oct; 35(10):1490-1500.e7. PubMed ID: 24139421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antithrombotic treatment as primary and secondary prevention of stroke].
    Chukanova EI; Chukanova AS; Nadareyshvili GG; Gulieva MS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10):85-88. PubMed ID: 28635860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
    Bath PM; Appleton JP; Beridze M; Christensen H; Dineen RA; Duley L; England TJ; Heptinstall S; James M; Krishnan K; Markus HS; Pocock S; Ranta A; Robinson TG; Flaherty K; Scutt P; Venables GS; Woodhouse LJ; Sprigg N
    Int J Stroke; 2017 Jul; 12(5):524-538. PubMed ID: 27811309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Platelet-function inhibitors in the secondary prevention of ischemic stroke].
    Busse O; Diener HC; Grond M
    Dtsch Med Wochenschr; 2006 Nov; 131 Suppl 5():S132-4. PubMed ID: 17089258
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiplatelet agents for stroke prevention following transient ischemic attack.
    Weinberger J
    South Med J; 2008 Jan; 101(1):70-8. PubMed ID: 18176296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
    Diener C
    MMW Fortschr Med; 2008 May; 150(21):7. PubMed ID: 18578065
    [No Abstract]   [Full Text] [Related]  

  • 37. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
    Simmons BB; Yeo A; Fung K; ;
    Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New insights in antiplatelet therapy for patients with ischemic stroke.
    Chaturvedi S; Bhattacharya P
    Neurologist; 2011 Sep; 17(5):255-62. PubMed ID: 21881467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [PRoFESS study presented. Change in secondary prevention].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():96-7. PubMed ID: 14579494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.